IDiyas

For the Inventor, By the Inventor

Chiba, Japan

Akira Nakagawara

USPTO Granted Patents = 12 


Average Co-Inventor Count = 1.5

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal11 out of 375 
 
Hisamitsu Pharmaceutical Company, Inc.
 patents
silverMedal9 out of 13 
 
Chiba-prefecture
 patents
bronzeMedal1 out of 4,916 
 
Ngk Insulators, Inc.
 patents
4. 1 out of 1 
 
Chiba-perfecture
 patent
5. 1 out of 1 
 
Eisamitsu Pharmaceutical Co., Ltd.
 patent
where one patent can have more than one assignee

Years Active: 2006-2012

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 8202690 - Cancer marker and therapeutic agent for cancer (2012-06-19),
2. 7985556 - Method of screening apoptosis accelerating compound or anti-apoptotic compound and method of determining malignancy of neurodegenerative disease (2011-07-26),
3. 7625711 - Screening method for the identification of a drug for the development of an agent for prevention and/or treatment of Alzheimer's disease (2009-12-01),
4. 7618787 - Method of screening compound capable of accelerating or inhibiting apoptosis, apoptosis accelarator and apoptosis inhibitor (2009-11-17),
5. 7601532 - Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma (2009-10-13),
6. 7429451 - Nucleic acids isolated from stage 4 neuroblastoma (2008-09-30),
7. 7384750 - Nucleic acid sequences having characteristics of enhanced expression in human neuroblastoma with favorable prognosis based on comparison between human neuroblastoma with favorable prognosis and human neuroblastoma with unfavorable prognosis (2008-06-10),
8. 7358349 - Nucleic acids having expression differentials between hepatoblastoma and normal liver (2008-04-15),
9. 7335755 - Nucleic acids isolated in neuroblastoma (2008-02-26),
10. 7238796 - Human BMCC1 gene (2007-07-03),
11. 7214782 - Nucleic acid of novel human kinesin-related gene protein encoded by the nucleic acid peptide fragment thereof and anticancer agents comprising the nucleic acid and the like (2007-05-08),
12. 7087383 - Nucleic acid sequences showing enhanced expression in benign neuroblastoma compared with acritical human neuroblastoma (2006-08-08),

Title: Akira Nakagawara: Innovator in Cancer Research

Introduction

Akira Nakagawara is a prominent inventor based in Chiba, Japan. He has made significant contributions to the field of cancer research, holding a total of 12 patents. His work focuses on developing novel methods for cancer detection and treatment.

Latest Patents

Among his latest patents is a groundbreaking cancer marker and therapeutic agent for cancer. This innovative marker allows for the detection of cancer by measuring the level of BMCC1 gene expression. The method is applicable to various types of cancer, including prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer. Another notable patent involves a method for screening apoptosis-accelerating compounds or anti-apoptotic compounds. This method assesses the interaction between p53 and NEDL1 in the presence and absence of a test compound, providing insights into the malignancy of neurodegenerative diseases.

Career Highlights

Throughout his career, Nakagawara has worked with notable organizations, including Hisamitsu Pharmaceutical Company, Inc. and the Chiba-prefecture. His expertise in cancer research has positioned him as a key figure in the scientific community.

Collaborations

He has collaborated with esteemed colleagues such as Toshinori Ozaki and Miki Ohira, who is a woman. These partnerships have further enhanced his research and contributions to the field.

Conclusion

Akira Nakagawara's innovative work in cancer research and his numerous patents highlight his dedication to advancing medical science. His contributions are paving the way for new methods of cancer detection and treatment, making a significant impact in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…